VN April 2024

Vetnews | April 2024 36 « BACK TO CONTENTS Introduction The growing interest in cannabis-based products, particularly Cannabidiol (CBD), for therapeutic purposes has extended into veterinary medicine. In South Africa, where the regulatory environment surrounding cannabis is evolving, veterinarians face unique challenges in integrating these products into their practice. Understanding the regulatory framework is crucial for veterinarians seeking to incorporate CBD and cannabis-based therapies into their practice. This article examines the regulatory framework governing the use of these products in veterinary medicine in South Africa. Regulatory Overview The regulatory landscape for CBD and cannabis products in South Africa is complex and constantly evolving. The primary legislation governing the use of cannabis is the Medicines and Related Substances Act of 1965 and its subsequent amendments. Under this act, cannabis used to be classified as a Schedule 7 substance, meaning it was strictly controlled and could only be used for medicinal purposes under specific conditions. In May 2020, the Minister of Health amended the Schedules with the following changes: • Cannabis, dronabinol, and tetrahydrocannabinol were deleted from Schedule and are now listed in Schedule 4 with the following exceptions: o Use in complementary medicines containing no more than 600 mg CBD per sales pack, providing a maximum daily dose of 20 mg of cannabidiol, and making a general health enhancement, health maintenance, or relief of minor symptoms (low risk) claim; or o Processed products made from cannabis raw plant material intended for ingestion containing 0,0075 % or less of CBD where only the naturally occurring quantity of cannabinoids found in the source material are contained in the product. These products are now regulated as Schedule 0 substances. • Transdelta-9-tetrahydrocannabinol (THC) is now listed in Schedule 6 with certain exceptions. These changes allowed for CBD-containing products to be available with a prescription from registered healthcare practitioners and veterinarians. SAHPRA oversees the registration, manufacturing, importation, and distribution of CBD and cannabis-based products intended for medicinal use. Manufacturers must adhere to Good Manufacturing Practice (GMP) standards to ensure product quality, safety, and efficacy. Additionally, labelling requirements mandate accurate product information, including CBD content, dosage instructions, and potential side effects. Veterinary Use of CBD and Cannabis Products South African Veterinarians may legally prescribe CBD-containing products for animals under their treatment. As with the use of all medicines, veterinarians are subject to Rule 10 of the Rules Relating to the Practicing of the Veterinary Professions. It is essential to note that CBD is not approved as a veterinary medicine by SAHPRA. Therefore, veterinarians must rely on extra-label prescribing and adhere to the prescriptions of Rule 10 (10) specifically dealing with extra-label use of medicines. This means that the veterinarian takes full responsibility for the use of the product and must be available to intervene if there are any aberrant reactions. Veterinarians Legal Mews NAVIGATING THE SOUTH AFRICAN REGULATORY LANDSCAPE: CBD AND CANNABIS PRODUCTS IN VETERINARY MEDICINE Trudie Prinsloo (Legalvet Services) This article is intended to provide information and educate veterinarians on relevant aspects of the law. It is not intended as personal legal advice. SAVA is not responsible or liable for any advice or other information provided herein.

RkJQdWJsaXNoZXIy OTc5MDU=